Carlotta Antoniotti
University of Pisa(IT)Azienda Ospedaliera Universitaria Pisana(IT)
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Cancer Genomics and Diagnostics, Gastric Cancer Management and Outcomes, Cancer Treatment and Pharmacology
Most-Cited Works
- → FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study(2015)1,081 cited
- → Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients(2015)1,079 cited
- → Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer(2015)492 cited
- → The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials(2020)327 cited
- → ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer(2017)323 cited
- → Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial(2020)